The ACTIVE Trial: A Prospective Randomised Control Trial Of The H1 Implant Versus Total Hip Replacement

Who can take part

• Patient requires unilateral primary hip arthroplasty due to primary osteoarthritis, osteoarthritis secondary to e.g. trauma, avascular necrosis or developmental hip dysplasia, or inflammatory arthritis
• Patient is willing to comply with study requirements
• Patient plans to be available through 10 years postoperative follow-up

Who cannot take part

• Patient has active infection or sepsis (treated or untreated)
• Patient has a BMI greater than 40 kg/m²
• Patient has insufficient bone stock at the hip (>1/3 necrosis of the femoral head or large and multiple cysts) or in general as in severe osteopenia or osteoporosis (t-score < -2.5 as measured with BMD)
• Patient is not skeletally mature
• Patient meets the contraindication criteria of the control device
• Patient already has another lower limb arthroplasty or arthrodesis or will require a further lower limb arthroplasty or arthrodesis within the subsequent 2 years
• Patient lacks capacity to consent
• Patient is unable to understand the native language of the country where their procedure is taking place